...Okay. Good morning, and thank you for joining the Cochlear results. For those of you online, I'm Dig Howitt, CEO. And what we'll do, I'll talk through result at high level, and then Brent will give more detail on the financials, and I'll come back with a recap on the outlook, and just to reinforce that our strategy is unchanged. So let's get underway. So the headline of this result is the Cochlear implant unit growth up 13%. I'll talk a bit about that, as we saw growth across developed markets and emerging markets. And on the back of the Profile Plus launch, it's very good to see that we are clearly regaining market share in key markets, and I'll talk more to that. Our Services revenue is up 5%. So again, we're getting a bit later in the cycle. With Nucleus 7, we're cycling high comps. So we're expecting, and we are seeing slower growth, but we continue to see some growth there. And Acoustics was below our expectations in the half with the decline in Acoustic sales, and I'll talk about...
